Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $71.91 USD
Change Today +3.05 / 4.43%
Volume 644.9K
KITE On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/15 - $89.21
52 Week Low
08/4/14 - $21.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. It has research collaboration and license agreement with Amgen Inc. to develop and commercialize various CAR-based product candidates; and collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

85 Employees
Last Reported Date: 05/15/15
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $387.2K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $502.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $218.8K
Vice President of Product Sciences
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc. and The Leukemia & Lymphoma Society Enters into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma

Kite Pharma, Inc. and The Leukemia & Lymphoma Society (LLS) announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Under the collaboration, LLS will launch a broad scope educational program focusing on CAR T-cell therapy for the treatment of blood cancers, as well as support outreach for clinical trial enrollment. LLS also will contribute up to $2.5 million, through the Therapy Acceleration Program (TAP), to help fund Kite's ongoing Phase 1/2 clinical study of KTE-C19, which is designed to evaluate safety and efficacy in the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), as well as two rare lymphomas – primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). Pivotal results from the KTE-C19 DLBCL study are expected in 2016 and, if promising, could lead to the potential launch and commercialization of KTE-C19 in 2017. Kite also plans to launch an additional three trials of KTE-C19 before the end of 2015 in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

Kite Pharma, Inc. and bluebird bio, Inc. announced that they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, including HPV-16 E6 TCR, currently in a Phase I study, and HPV-16 E7 TCR. The collaboration brings together the powerful technologies and capabilities of these two leading immunotherapy companies. Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells. Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, including research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.

Adimab, LLC Establishes New Collaboration with Kite Pharma, Inc. for the Discovery of Antibodies for T-Cell Therapies

Adimab, LLC announced a new collaboration with Kite Pharma, Inc. Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite. For each target, the agreement grants Kite the right to research antibodies generated during the collaboration for potential use in therapeutic CAR-T products. Kite will also have the option to exclusively license antibodies for development and commercialization as therapeutic CAR products. Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic CAR product sales that are optioned under the agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $71.91 USD +3.05

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies

Industry Analysis


Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,015.0x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 880.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at